| Literature DB >> 30072899 |
San-Yuan Chen1,2, Ying-Ray Lee3, Ming-Chia Hsieh4, Hany A Omar5,6, Yen-Ni Teng7, Ching-Yen Lin3, Jui-Hsiang Hung8,9.
Abstract
Antrodia cinnamomea (AC) is a medicinal fungal species that has been widely used traditionally in Taiwan for the treatment of diverse health-related conditions including cancer. It possesses potent anti-inflammatory and antioxidant properties in addition to its ability to promote cancer cell death in several human tumors. Our aim was to improve the anticancer activity of AC in hepatocellular carcinoma (HCC) through its cocultivation with ginger aiming at tuning the active ingredients. HCC cell lines, Huh-7 and HepG2 were used to study the in vitro anticancer activity of the ethanolic extracts of AC (EAC) alone or after the cocultivation in presence of ginger (EACG). The results indicated that the cocultivation of AC with ginger significantly induced the production of important triterpenoids and EACG was significantly more potent than EAC in targeting HCC cell lines. EACG effectively inhibited cancer cells growth via the induction of cell cycle arrest at G2/M phase and induction of apoptosis in Huh-7 and HepG2 cells as indicated by MTT assay, cell cycle analysis, Annexin V assay, and the activation of caspase-3. In addition, EACG modulated cyclin proteins expression and mitogen-activated protein kinase (MAPK) signaling pathways in favor of the inhibition of cancer cell survival. Taken together, the current study highlights an evidence that EACG is superior to EAC in targeting cancer cell survival and inducing apoptotic cell death in HCC. These findings support that EACG formula can serve as a potential candidate for HCC adjuvant therapy.Entities:
Keywords: Antrodia cinnamomea; MAPK; adjuvant therapy; apoptosis; cell cycle; ginger; hepatocellular carcinoma
Year: 2018 PMID: 30072899 PMCID: PMC6058215 DOI: 10.3389/fphar.2018.00780
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
The major triterpenoids in different A. cinnamomea extracts.
| Number | M.W | Compound |
|---|---|---|
| 1 | 482 | Methyl antcinate B |
| 2 | 468 | Dehydroeburicoic acid/Antcin B/Methyl antcinate A |
| 3 | 526 | 15α-acetyl dehydrosulphurenic acid |
| 4 | 470 | 3β,15α-dihydroxy-lanosta-7,9(11),24-triene-21-oic acid |
| 5 | 484 | Dehydrosulphurenic acid |
| 6 | 486 | Zhankuic acid C |
| 7 | 488 | Antcin K |
| 8 | 454 | Antcin A |
The IC50 values of EAC and EACG in Huh-7 and HepG2 cells based on MTT cell viability analysis.
| Treatment | Huh-7 (IC50 μg/ml) | HepG2 (IC50 μg/ml) |
|---|---|---|
| EAC | 245.40 ± 2.45 | 51.93 ± 2.18 |
| EACG | 50.33 ± 3.66 | 8.35 ± 0.97 |
The effect of EAC and EACG on cell cycle distribution in Huh-7 cells.
| sub-G1 | G0/G1 | S | G2/M | ||
|---|---|---|---|---|---|
| 24 h | Control | 0.08 – 0.08 | 63.05 – 1.58 | 14.91 – 0.37 | 21.38 – 0.26 |
| EAC | 0.56 – 0.27 | 63.52 – 0.53 | 14.41 – 0.76 | 19.84 – 0.87 | |
| EACG | 0.00 – 0.00 | 44.47 – 0.69* | 17.95 – 0.24* | 33.65 – 0.52** | |
| 36 h | Control | 0.37 – 0.06 | 69.83 – 1.55 | 10.94 – 0.61 | 17.64 – 0.13 |
| EAC | 0.30 – 0.23 | 66.36 – 2.07 | 11.87 – 0.68 | 20.62 – 0.70 | |
| EACG | 17.78 – 0.45*** | 27.75 – 1.63*** | 19.22 – 1.12** | 32.64 – 0.91** |